A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain
A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain
The purpose of this study is to examine the effects of various increasing doses of Ralfinamide in patients with neuropathic pain.
Inclusion Criteria:
Exclusion Criteria:
Brno-Bhunice, Czechia
Pizen, Czechia
Pradesh, India
Grassi, Italy
Bialobrzeska, Poland
West Midlands, United Kingdom